Prescription Pharmaceuticals Market – Industry Analysis and Forecast (2019 – 2026) _ by Therapeutic Segments (Cardiovascular Disorders, Inflammatory Conditions and Others), by Formulations (Capsules, Inhalants, Parenterals and Other), Geography

Market Scenario

Prescription Pharmaceuticals Market is expected to grow from USD 771.23 billion in 2018 and reach USD XX billion by 2026, growing at  a CAGR of XX% from 2018 to 2026(Detailed analysis of the market CAGR is provided in the report)Prescription Pharmaceuticals Market. Prescription Pharmaceuticals MarketThe report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Key Highlights: • Prescription Pharmaceuticals market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Prescription Pharmaceuticals market. • Prescription Pharmaceuticals market segmentation on the basic product, service, and geography (country-wise) has been provided. • Prescription Pharmaceuticals market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of the study. • Prescription Pharmaceuticals market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Prescription Pharmaceuticals market are also profiled. For company profiles, 2017 has been considered as the base year. In cases, wherein information was unavailable for the base year, the years prior to it have been considered. Research Methodology: The market is estimated by triangulation of data points obtained from various sources and feeding them into a simulation model created individually for each market. The data points are obtained from paid and unpaid sources along with paid primary interviews with key opinion leaders (KOLs) in the market. KOLs from both, demand and supply side were considered while conducting interviews to get an unbiased idea of the market. This exercise was done at a country level to get a fair idea of the market in countries considered for this study. Later this country-specific data was accumulated to come up with regional numbers and then arrive at the global market value for Prescription Pharmaceuticals Market. Key players in the Global Prescription Pharmaceuticals market are • Bayer AG • AstraZeneca • Gilead Sciences • Johnson & Johnson • GlaxoSmithKline • Novartis A.G. • Merck & Co. • Pfizer • Sanofi S.A • F. Hoffmann-La Roche Key Target Audience: • Research and consulting companies • Global Prescription Pharmaceuticals market Investors • Organization associated with Research and Development (R&D) • Global Prescription Pharmaceuticals marketing players • Academic medical centers and universities

Scope of the Prescription Pharmaceuticals Market report:

Research report categorizes the Global Prescription Pharmaceuticals market based on Therapeutic Segments, Formulations and geography. Market size by value is estimated and forecasted with the revenues of leading companies operating in the Global Prescription Pharmaceuticals market with key developments in companies and market trends

Prescription Pharmaceuticals Market, By Therapeutic Segments

• Cardiovascular Disorders • Oncology • Inflammatory Conditions • Infectious Diseases • Metabolic Disorders • Respiratory Disorders • Other Therapeutic Segments

Prescription Pharmaceuticals Market, By Formulations

• Capsules • Tablets • Inhalants and Liquids • Parenterals • Topicals

Prescription Pharmaceuticals market, by Geography:

• North America • Europe • Asia Pacific • Middle East & Africa • Latin America Available Customization Maximize Market Research offers customization of report and scope of the report as per the specific requirement of our client

Table of Contents

Global Prescription Pharmaceuticals Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Prescription Pharmaceuticals Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Prescription Pharmaceuticals Market Analysis and Forecast 6.1. Global Prescription Pharmaceuticals Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Prescription Pharmaceuticals Market Analysis and Forecast, by Therapeutic Segments 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Prescription Pharmaceuticals Market Value Share Analysis, by Therapeutic Segments 7.4. Global Prescription Pharmaceuticals Market Size (US$ Bn) Forecast, by Therapeutic Segments 7.5. Global Prescription Pharmaceuticals Market Analysis, by Therapeutic Segments 7.6. Global Prescription Pharmaceuticals Market Attractiveness Analysis, by Therapeutic Segments 8. Global Prescription Pharmaceuticals Market Analysis and Forecast, by Formulations 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Prescription Pharmaceuticals Market Value Share Analysis, by Formulations 8.4. Global Prescription Pharmaceuticals Market Size (US$ Bn) Forecast, by Formulations 8.5. Global Prescription Pharmaceuticals Market Analysis, by Formulations 8.6. Global Prescription Pharmaceuticals Market Attractiveness Analysis, by Formulations 9. Global Prescription Pharmaceuticals Market Analysis, by Region 9.1. Global Prescription Pharmaceuticals Market Value Share Analysis, by Region 9.2. Global Prescription Pharmaceuticals Market Size (US$ Bn) Forecast, by Region 9.3. Global Prescription Pharmaceuticals Market Attractiveness Analysis, by Region 10. North America Prescription Pharmaceuticals Market Analysis 10.1. Key Findings 10.2. North America Prescription Pharmaceuticals Market Overview 10.3. North America Prescription Pharmaceuticals Market Value Share Analysis, by Therapeutic Segments 10.4. North America Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 10.4.1. Cardiovascular Disorders 10.4.2. Oncology 10.4.3. Inflammatory Conditions 10.4.4. Infectious Diseases 10.4.5. Metabolic Disorders 10.4.6. Respiratory Disorders 10.4.7. Others 10.5. North America Prescription Pharmaceuticals Market Value Share Analysis, by Formulations 10.6. North America Prescription Pharmaceuticals Market Forecast, by Formulations 10.6.1. Capsules 10.6.2. Tablets 10.6.3. Inhalants and Liquids 10.6.4. Parenterals 10.6.5. Topicals 10.7. North America Prescription Pharmaceuticals Market Value Share Analysis, by Country 10.8. North America Prescription Pharmaceuticals Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Prescription Pharmaceuticals Market Analysis, by Country 10.10. U.S. Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 10.10.1. Cardiovascular Disorders 10.10.2. Oncology 10.10.3. Inflammatory Conditions 10.10.4. Infectious Diseases 10.10.5. Metabolic Disorders 10.10.6. Respiratory Disorders 10.10.7. Others 10.11. U.S. Prescription Pharmaceuticals Market Forecast, by Formulations 10.11.1. Capsules 10.11.2. Tablets 10.11.3. Inhalants and Liquids 10.11.4. Parenterals 10.11.5. Topicals 10.12. Canada Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 10.12.1. Cardiovascular Disorders 10.12.2. Oncology 10.12.3. Inflammatory Conditions 10.12.4. Infectious Diseases 10.12.5. Metabolic Disorders 10.12.6. Respiratory Disorders 10.12.7. Others 10.13. Canada Prescription Pharmaceuticals Market Forecast, by Formulations 10.13.1. Capsules 10.13.2. Tablets 10.13.3. Inhalants and Liquids 10.13.4. Parenterals 10.13.5. Topicals 10.14. North America Prescription Pharmaceuticals Market Attractiveness Analysis 10.14.1. By Therapeutic Segments 10.14.2. by Formulations 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Prescription Pharmaceuticals Market Analysis 11.1. Key Findings 11.2. Europe Prescription Pharmaceuticals Market Overview 11.3. Europe Prescription Pharmaceuticals Market Value Share Analysis, by Therapeutic Segments 11.4. Europe Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 11.4.1. Cardiovascular Disorders 11.4.2. Oncology 11.4.3. Inflammatory Conditions 11.4.4. Infectious Diseases 11.4.5. Metabolic Disorders 11.4.6. Respiratory Disorders 11.4.7. Others 11.5. Europe Prescription Pharmaceuticals Market Value Share Analysis, by Formulations 11.6. Europe Prescription Pharmaceuticals Market Forecast, by Formulations 11.6.1. Capsules 11.6.2. Tablets 11.6.3. Inhalants and Liquids 11.6.4. Parenterals 11.6.5. Topicals 11.6.6. Europe Prescription Pharmaceuticals Market Value Share Analysis, by Country 11.7. Europe Prescription Pharmaceuticals Market Forecast, by Country 11.7.1. Germany 11.7.2. U.K. 11.7.3. France 11.7.4. Italy 11.7.5. Spain 11.7.6. Rest of Europe 11.8. Europe Prescription Pharmaceuticals Market Analysis, by Country 11.9. Germany Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 11.9.1. Cardiovascular Disorders 11.9.2. Oncology 11.9.3. Inflammatory Conditions 11.9.4. Infectious Diseases 11.9.5. Metabolic Disorders 11.9.6. Respiratory Disorders 11.9.7. Others 11.10. Germany Prescription Pharmaceuticals Market Forecast, by Formulations 11.10.1. Capsules 11.10.2. Tablets 11.10.3. Inhalants and Liquids 11.10.4. Parenterals 11.10.5. Topicals 11.11. U.K. Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 11.11.1. Cardiovascular Disorders 11.11.2. Oncology 11.11.3. Inflammatory Conditions 11.11.4. Infectious Diseases 11.11.5. Metabolic Disorders 11.11.6. Respiratory Disorders 11.11.7. Others 11.12. U.K. Prescription Pharmaceuticals Market Forecast, by Formulations 11.12.1. Capsules 11.12.2. Tablets 11.12.3. Inhalants and Liquids 11.12.4. Parenterals 11.12.5. Topicals 11.13. France Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 11.13.1. Cardiovascular Disorders 11.13.2. Oncology 11.13.3. Inflammatory Conditions 11.13.4. Infectious Diseases 11.13.5. Metabolic Disorders 11.13.6. Respiratory Disorders 11.13.7. Others 11.14. France Prescription Pharmaceuticals Market Forecast, by Formulations 11.14.1. Capsules 11.14.2. Tablets 11.14.3. Inhalants and Liquids 11.14.4. Parenterals 11.14.5. Topicals 11.15. Italy Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 11.15.1. Cardiovascular Disorders 11.15.2. Oncology 11.15.3. Inflammatory Conditions 11.15.4. Infectious Diseases 11.15.5. Metabolic Disorders 11.15.6. Respiratory Disorders 11.15.7. Others 11.16. Italy Prescription Pharmaceuticals Market Forecast, by Formulations 11.16.1. Capsules 11.16.2. Tablets 11.16.3. Inhalants and Liquids 11.16.4. Parenterals 11.16.5. Topicals 11.17. Spain Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 11.17.1. Cardiovascular Disorders 11.17.2. Oncology 11.17.3. Inflammatory Conditions 11.17.4. Infectious Diseases 11.17.5. Metabolic Disorders 11.17.6. Respiratory Disorders 11.17.7. Others 11.18. Spain Prescription Pharmaceuticals Market Forecast, by Formulations 11.18.1. Capsules 11.18.2. Tablets 11.18.3. Inhalants and Liquids 11.18.4. Parenterals 11.18.5. Topicals 11.19. Rest of Europe Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 11.19.1. Cardiovascular Disorders 11.19.2. Oncology 11.19.3. Inflammatory Conditions 11.19.4. Infectious Diseases 11.19.5. Metabolic Disorders 11.19.6. Respiratory Disorders 11.19.7. Others 11.20. Rest of Europe Prescription Pharmaceuticals Market Forecast, by Formulations 11.20.1. Capsules 11.20.2. Tablets 11.20.3. Inhalants and Liquids 11.20.4. Parenterals 11.20.5. Topicals 11.21. Europe Prescription Pharmaceuticals Market Attractiveness Analysis 11.21.1. By Therapeutic Segments 11.21.2. by Formulations 11.22. PEST Analysis 11.23. Key Trend 11.24. Key Development 12. Asia Pacific Prescription Pharmaceuticals Market Analysis 12.1. Key Findings 12.2. Asia Pacific Prescription Pharmaceuticals Market Overview 12.3. Asia Pacific Prescription Pharmaceuticals Market Value Share Analysis, by Therapeutic Segments 12.4. Asia Pacific Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 12.4.1. Cardiovascular Disorders 12.4.2. Oncology 12.4.3. Inflammatory Conditions 12.4.4. Infectious Diseases 12.4.5. Metabolic Disorders 12.4.6. Respiratory Disorders 12.4.7. Others 12.5. Asia Pacific Prescription Pharmaceuticals Market Value Share Analysis, by Formulations 12.6. Asia Pacific Prescription Pharmaceuticals Market Forecast, by Formulations 12.6.1. Capsules 12.6.2. Tablets 12.6.3. Inhalants and Liquids 12.6.4. Parenterals 12.6.5. Topicals 12.7. Asia Pacific Prescription Pharmaceuticals Market Value Share Analysis, by Country 12.8. Asia Pacific Prescription Pharmaceuticals Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Prescription Pharmaceuticals Market Analysis, by Country 12.10. China Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 12.10.1. Cardiovascular Disorders 12.10.2. Oncology 12.10.3. Inflammatory Conditions 12.10.4. Infectious Diseases 12.10.5. Metabolic Disorders 12.10.6. Respiratory Disorders 12.10.7. Others 12.11. China Prescription Pharmaceuticals Market Forecast, by Formulations 12.11.1. Capsules 12.11.2. Tablets 12.11.3. Inhalants and Liquids 12.11.4. Parenterals 12.11.5. Topicals 12.12. India Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 12.12.1. Cardiovascular Disorders 12.12.2. Oncology 12.12.3. Inflammatory Conditions 12.12.4. Infectious Diseases 12.12.5. Metabolic Disorders 12.12.6. Respiratory Disorders 12.12.7. Others 12.13. India Prescription Pharmaceuticals Market Forecast, by Formulations 12.13.1. Capsules 12.13.2. Tablets 12.13.3. Inhalants and Liquids 12.13.4. Parenterals 12.13.5. Topicals 12.14. Japan Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 12.14.1. Cardiovascular Disorders 12.14.2. Oncology 12.14.3. Inflammatory Conditions 12.14.4. Infectious Diseases 12.14.5. Metabolic Disorders 12.14.6. Respiratory Disorders 12.14.7. Others 12.15. Japan Prescription Pharmaceuticals Market Forecast, by Formulations 12.15.1. Capsules 12.15.2. Tablets 12.15.3. Inhalants and Liquids 12.15.4. Parenterals 12.15.5. Topicals 12.16. ASEAN Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 12.16.1. Cardiovascular Disorders 12.16.2. Oncology 12.16.3. Inflammatory Conditions 12.16.4. Infectious Diseases 12.16.5. Metabolic Disorders 12.16.6. Respiratory Disorders 12.16.7. Others 12.17. ASEAN Prescription Pharmaceuticals Market Forecast, by Formulations 12.17.1. Capsules 12.17.2. Tablets 12.17.3. Inhalants and Liquids 12.17.4. Parenterals 12.17.5. Topicals 12.18. Rest of Asia Pacific Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 12.18.1. Cardiovascular Disorders 12.18.2. Oncology 12.18.3. Inflammatory Conditions 12.18.4. Infectious Diseases 12.18.5. Metabolic Disorders 12.18.6. Respiratory Disorders 12.18.7. Others 12.19. Rest of Asia Pacific Prescription Pharmaceuticals Market Forecast, by Formulations 12.19.1. Capsules 12.19.2. Tablets 12.19.3. Inhalants and Liquids 12.19.4. Parenterals 12.19.5. Topicals 12.20. Asia Pacific Prescription Pharmaceuticals Market Attractiveness Analysis 12.20.1. By Therapeutic Segments 12.20.2. by Formulations 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Prescription Pharmaceuticals Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Prescription Pharmaceuticals Market Overview 13.3. Middle East & Africa Prescription Pharmaceuticals Market Value Share Analysis, by Therapeutic Segments 13.4. Middle East & Africa Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 13.4.1. Cardiovascular Disorders 13.4.2. Oncology 13.4.3. Inflammatory Conditions 13.4.4. Infectious Diseases 13.4.5. Metabolic Disorders 13.4.6. Respiratory Disorders 13.4.7. Others 13.5. Middle East & Africa Prescription Pharmaceuticals Market Value Share Analysis, by Formulations 13.6. Middle East & Africa Prescription Pharmaceuticals Market Forecast, by Formulations 13.6.1. Capsules 13.6.2. Tablets 13.6.3. Inhalants and Liquids 13.6.4. Parenterals 13.6.5. Topicals 13.7. Middle East & Africa Prescription Pharmaceuticals Market Value Share Analysis, by Country 13.8. Middle East & Africa Prescription Pharmaceuticals Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Prescription Pharmaceuticals Market Analysis, by Country 13.10. GCC Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 13.10.1. Cardiovascular Disorders 13.10.2. Oncology 13.10.3. Inflammatory Conditions 13.10.4. Infectious Diseases 13.10.5. Metabolic Disorders 13.10.6. Respiratory Disorders 13.10.7. Others 13.11. GCC Prescription Pharmaceuticals Market Forecast, by Formulations 13.11.1. Capsules 13.11.2. Tablets 13.11.3. Inhalants and Liquids 13.11.4. Parenterals 13.11.5. Topicals 13.12. South Africa Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 13.12.1. Cardiovascular Disorders 13.12.2. Oncology 13.12.3. Inflammatory Conditions 13.12.4. Infectious Diseases 13.12.5. Metabolic Disorders 13.12.6. Respiratory Disorders 13.12.7. Others 13.13. South Africa Prescription Pharmaceuticals Market Forecast, by Formulations 13.13.1. Capsules 13.13.2. Tablets 13.13.3. Inhalants and Liquids 13.13.4. Parenterals 13.13.5. Topicals 13.14. Rest of Middle East & Africa Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 13.14.1. Cardiovascular Disorders 13.14.2. Oncology 13.14.3. Inflammatory Conditions 13.14.4. Infectious Diseases 13.14.5. Metabolic Disorders 13.14.6. Respiratory Disorders 13.14.7. Others 13.15. Rest of Middle East & Africa Prescription Pharmaceuticals Market Forecast, by Formulations 13.15.1. Capsules 13.15.2. Tablets 13.15.3. Inhalants and Liquids 13.15.4. Parenterals 13.15.5. Topicals 13.16. Middle East & Africa Prescription Pharmaceuticals Market Attractiveness Analysis 13.16.1. By Therapeutic Segments 13.16.2. by Formulations 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Prescription Pharmaceuticals Market Analysis 14.1. Key Findings 14.2. South America Prescription Pharmaceuticals Market Overview 14.3. South America Prescription Pharmaceuticals Market Value Share Analysis, by Therapeutic Segments 14.4. South America Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 14.4.1. Cardiovascular Disorders 14.4.2. Oncology 14.4.3. Inflammatory Conditions 14.4.4. Infectious Diseases 14.4.5. Metabolic Disorders 14.4.6. Respiratory Disorders 14.4.7. Others 14.5. Others South America Prescription Pharmaceuticals Market Value Share Analysis, by Formulations 14.6. South America Prescription Pharmaceuticals Market Forecast, by Formulations 14.6.1. Capsules 14.6.2. Tablets 14.6.3. Inhalants and Liquids 14.6.4. Parenterals 14.6.5. Topicals 14.7. South America Prescription Pharmaceuticals Market Value Share Analysis, by Country 14.8. South America Prescription Pharmaceuticals Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 14.9.1. Cardiovascular Disorders 14.9.2. Oncology 14.9.3. Inflammatory Conditions 14.9.4. Infectious Diseases 14.9.5. Metabolic Disorders 14.9.6. Respiratory Disorders 14.9.7. Others 14.10. Brazil Prescription Pharmaceuticals Market Forecast, by Formulations 14.10.1. Capsules 14.10.2. Tablets 14.10.3. Inhalants and Liquids 14.10.4. Parenterals 14.10.5. Topicals 14.11. Mexico Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 14.11.1. Cardiovascular Disorders 14.11.2. Oncology 14.11.3. Inflammatory Conditions 14.11.4. Infectious Diseases 14.11.5. Metabolic Disorders 14.11.6. Respiratory Disorders 14.11.7. Others 14.12. Mexico Prescription Pharmaceuticals Market Forecast, by Formulations 14.12.1. Capsules 14.12.2. Tablets 14.12.3. Inhalants and Liquids 14.12.4. Parenterals 14.12.5. Topicals 14.13. Rest of South America Prescription Pharmaceuticals Market Forecast, by Therapeutic Segments 14.13.1. Cardiovascular Disorders 14.13.2. Oncology 14.13.3. Inflammatory Conditions 14.13.4. Infectious Diseases 14.13.5. Metabolic Disorders 14.13.6. Respiratory Disorders 14.13.7. Others 14.14. Rest of South America Prescription Pharmaceuticals Market Forecast, by Formulations 14.14.1. Capsules 14.14.2. Tablets 14.14.3. Inhalants and Liquids 14.14.4. Parenterals 14.14.5. Topicals 14.15. South America Prescription Pharmaceuticals Market Attractiveness Analysis 14.15.1. By Therapeutic Segments 14.15.2. by Formulations 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Formulations Launches and Formulations Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Bayer AG 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Formulations Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Manufacturing Footprint 15.3.2. AstraZeneca 15.3.3. Gilead Sciences 15.3.4. Johnson & Johnson 15.3.5. GlaxoSmithKline 15.3.6. Novartis A.G. 15.3.7. Merck & Co. 15.3.8. Pfizer 15.3.9. Sanofi S.A 15.3.10. F. Hoffmann-La Roche 16. Primary Key Insights

About This Report

Report ID 330
Category Healthcare
Published Date Nov 2019
No of Pages 186
Contact Us